Finafloxacin 300 mg Twice a Day (b.i.d.) Versus Ciprofloxacin 250 mg Twice a Day (b.i.d) in Patients With Lower Uncomplicated UTI (uUTI)

NCT ID: NCT00722735

Last Updated: 2009-06-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-10-31
• Study Completion Date: 2009-04-30

Brief Summary

To compare the bacteriological eradication rates of Finafloxacin and Ciprofloxacin in female patients with uUTI.

Detailed Description

Patients with clinical signs and symptoms of uUTI who have a high probability of the required number of bacteria in their urine, measured by positive test for nitrite and /or leucocyte esterase by means of a dipstick will be enrolled in this study. Only these patients with bacterial count equal or more than 10e5 cfu/mL will be included in the efficacy analysis. At Baseline, patients will be randomly assigned (2:1) to receive Finafloxacin 300 mg or Ciprofloxacin 250 mg, following a double-dummy design, ie Group 1 will receive Finafloxacin tablets + Ciprofloxacin placebo capsule while Group II will receive Ciprofloxacin capsule + Finafloxacin placebo tablets. The treatment will last in total 3 days. The microbiological results will be compared with the baseline microbiology. If the concentration of initial pathogen in the urine is equal or more than 10e3 cfu/mL in the post-therapy culture compared with the baseline , this will define a bacteriological eradication. Microbiological assessment will be performed as well. Evaluation of the bacteria reinfection or relapse will be performed, based on the microbiology results. The status of clinical improvement and cure will be considered additionally.

Conditions

Urinary Tract Infections

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

1

Group I: Finafloxacin tablets + Ciprofloxacin placebo capsule

Group Type: EXPERIMENTAL

Finafloxacin

Intervention Type: DRUG

Finafloxacin tablets, 300 mg b.i.d., oral administration; Ciprofloxacin placebo capsule, 1 capsule b.i.d.,oral administration; duration: 3 days

2

Group II: Ciprofloxacin capsule + Finafloxacin placebo tablets

Group Type: ACTIVE_COMPARATOR

Ciprofloxacin

Intervention Type: DRUG

Finafloxacin placebo, 6 tablets b.i.d., oral administration; Ciprofloxacin capsule, 250 mg b.i.d., oral administration; duration: 3 days

Interventions

Finafloxacin

Finafloxacin tablets, 300 mg b.i.d., oral administration; Ciprofloxacin placebo capsule, 1 capsule b.i.d.,oral administration; duration: 3 days

Intervention Type: DRUG

Ciprofloxacin

Finafloxacin placebo, 6 tablets b.i.d., oral administration; Ciprofloxacin capsule, 250 mg b.i.d., oral administration; duration: 3 days

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Female patients between 18 and 55 years with uUTI.

2. Two of the following sign and symptoms of uUTI: dysuria, frequency, urgency, miction pain, suprapubic pain, gross hematuria, turbid urine or malodorous urine.

3. Able to supply a mid-stream, clean catch urine sample for microbiological analysis.

4. The result of the dipstick should indicate a high probability of the required number of bacteria.

5. Be able to communicate with the study personnel.

6. Has given written consent to participate in the study.

Exclusion Criteria

1. Female patients having signs and symptoms of upper urinary tract infection (e.g. fever, flank pain) indicating complicated UTI.

2. Male patients

3. History or evidence of other functional or anatomical abnormalities of the urinary tract (e.g. acute pyelonephritis), diabetes mellitus and immunosuppression.

4. Recurrent cystitis with more than 3 episodes in the past 12 months.

5. Clinical symptoms for more than 7 days before Baseline.

6. Psychiatric, neurological or behavior disorders.

7. Clinically significant serious unstable physical illness.

8. Known uncontrolled condition of hypertension or symptomatic hypotension, known ischemic heart disease or history of myocardial infarction (within 12 months prior study enrolment), coronary artery bypass surgery or percutaneous transluminal coronary angioplasty.

9. Existence of any surgical or medical condition which might interfere with the distribution, metabolism or excretion of the drug, i.e. impaired renal or hepatic function, diabetes mellitus, chronic symptoms of pronounced constipation or diarrhea or conditions associated with total or partial obstruction of the urinary tract.

10. Antibiotic intake 2 weeks before study enrolment.

11. Failed UTI therapy within 2 months before study inclusion.

12. Expectancy of concomitant administration of antibiotics, sucralfate or divalent and trivalent cations such as iron or antacids containing magnesium, aluminium or calcium intake during the course of the study.

13. Clinically abnormal vital signs, ECG findings and safety laboratory results at Baseline.

14. Known hypersensitivity or contraindication to the use of fluoroquinolones.

15. History of tendon lesions or ruptures during quinolone treatment.

16. Any malignant disease or a history of malignant neoplasm other than carcinoma in situ of the cervix or basal cell carcinoma of the skin, within the last 5 years before Baseline.

17. Current diagnosis or history of substance abuse.

18. Exposure to any of the investigational drugs 30 days prior to Baseline.

19. Pregnant or nursing woman, or woman of childbearing potential who is not using an effective contraceptive method during the study, e.g. oral (stable doses for at least 3 months prior to Baseline) or injectable (stable doses for at least 2 months prior to Baseline) contraceptives, intrauterine devices (for at least 2 months prior Baseline), double-barrier method, contraceptive patch, female sterilization or condoms.

20. The patient, planned to be enrolled is an employee of any involved study investigator or any involved institution including the study sponsor.

21. Inability or lacking motivation to participate in the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

MerLion Pharmaceuticals GmbH

INDUSTRY

Sponsor Role: lead

Responsible Party

Practicing Physician

Principal Investigators

Jasper Hein, MD

Role: PRINCIPAL_INVESTIGATOR

Locations

Medical practice, Dr. J. Hein (Principal Study Investigator)

Marburg, , Germany

National University Hospital

Singapore, , Singapore

Countries

Germany; Singapore

References

Vente A, Bentley C, Luckermann M, Tambyah P, Dalhoff A. Early Clinical Assessment of the Antimicrobial Activity of Finafloxacin Compared to Ciprofloxacin in Subsets of Microbiologically Characterized Isolates. Antimicrob Agents Chemother. 2018 Mar 27;62(4):e02325-17. doi: 10.1128/AAC.02325-17. Print 2018 Apr.

Reference Type: DERIVED

PMID: 29339393 (View on PubMed)

Other Identifiers

FINA-003

Identifier Type: -

Identifier Source: org_study_id